Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

n and our financial performance.

Our actual results may vary depending on a variety of factors, including:

  • the development of competitive generic versions of oral Vancocin;
  • our ability to successfully commercialize Cinryze;
  • our ability to receive regulatory approval for the use of Cinryze for the acute treatment of HAE;
  • the availability of third party payer reimbursement for Cinryze patients;
  • our ability to develop a clinical development program for maribavir;
  • approval of products which are currently marketed for other indications by other companies or new pharmaceuticals and technological advances to treat the conditions addressed by Vancocin or Cinryze;
  • fluctuations in wholesaler order patterns and inventory levels;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for the product;
  • changes in prescribing or procedural practices of physicians, including off-label prescribing of products competitive with Vancocin and Cinryze;
  • the timing of regulatory submissions and approvals;
  • actions by the FDA, EMEA and the Internal Revenue Service or other government regulatory agencies;
  • decreases in the rate of infections for which Vancocin is prescribed or decreases in the sensitivity of the relevant bacteria to Vancocin;
  • an impairment of our intangible assets if our market capitalization remains less than our book value;
  • the timing and results of anticipated events in our clinical development programs; and
  • the timing and nature of potential business development activities related to our efforts to expand our current portfolio through in-licensing or other means of acquiring produ
    '/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... colleagues from University of California Los Angeles, Boston University School of Medicine, Frederick ... appears in PLOS One, the world’s first multidisciplinary Open Access journal. , ...
(Date:9/1/2015)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... Board of Directors as a Non-Executive Director. Sara will also ... of the Shire Board. Both appointments will be effective as ... Chairman, President and Chief Executive Officer of Dun & Bradstreet, ... at D&B, she helped drive the transformation of the company ...
(Date:8/31/2015)... ON , Aug. 31, 2015 /PRNewswire/ - BIOREM Inc. ... orders totalling $5.7 million. The orders are for air emission abatement ... "Of particular note is a large order for a municipality ... equipment will be replacing a competitor,s system that failed to ... in our engineered solutions," said Derek S. Webb , ...
(Date:8/31/2015)... MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) aclinical ... lead antibody, HuMab 5B1, will be garnering major attention ... upcoming World Molecular Imaging Congress (WMIC) being held in ... from the Department of Radiology at Memorial Sloan Kettering ... of MabVax,s lead antibody as a PET imaging agent ...
Breaking Biology Technology:Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Shire Appoints Sara Mathew to Board of Directors 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4
... Engineering News (Volume 26, No. 11) , , ... one's own shop, even for a period longer than a year, ... filed later to protect the invention. , ,This rule was pronounced ... patent asserted that the patent was invalid due to prior public ...
... Wis. - A new combination of technical solutions ... publishing, broadcasting, and graphic design to transfer high-definition video ... joint solution promises Apple Mac OS X users in ... reduce the time demand for specialized data transfer tasks. ...
... the biotech industry? The July 2006 edition of MedAd News ... birthday this year. On Aug, 23, 2004, I wrote an article ... Boston, Geneva, or Chicago? " , ,In this article I reviewed ... that date the industry back to the 1970s and perhaps the ...
Cached Biology Technology:With patents and research tools, when is private really public? 2With patents and research tools, when is private really public? 3With patents and research tools, when is private really public? 4With patents and research tools, when is private really public? 5Small Tree branches out with affordable video 2At 30, biotech is an industry at a crossroads 2At 30, biotech is an industry at a crossroads 3At 30, biotech is an industry at a crossroads 4At 30, biotech is an industry at a crossroads 5At 30, biotech is an industry at a crossroads 6At 30, biotech is an industry at a crossroads 7
(Date:8/24/2015)... August 24, 2015 The consulting company ... largest biometrics manufacturer DERMALOG and its customized solutions and products ... Biometrics Company of the Year Award". DERMALOG is particularly successful ... .   -Cross reference: Picture is available at ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/17/2015)... Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... campaign for Q4 2015. The new marketing campaign is ... of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ... a leader in retail driven marketing and brand awareness ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... for centuries that copper is a potent weapon against ... serious urinary tract infections "know" this, too, and steal ... them. Blocking this thievery with a drug ... according to researchers at Washington University School of Medicine ...
... Calif.) An evaluation of national data by UC Davis researchers ... higher risk of death. When compared to those with ... risk of death during a follow-up period of six years. People ... if they also had diabetes or hypertension. The findings, ...
... be a breakthrough in the practical application of epigenetic ... that those with osteoarthritis have a signature epigenetic change ... gene that produces a destructive enzyme called MMP13. This ... destruction of joint cartilage, making MMP13 and the epigenetic ...
Cached Biology News:Urinary tract infections steal from hosts' defense arsenals 2UC Davis study finds that above-normal weight alone does not increase the short-term risk of death 2UC Davis study finds that above-normal weight alone does not increase the short-term risk of death 3Scientists discover an epigenetic cause of osteoarthritis 2
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... c-Jun proto-oncogene was first identified as the cellular ... Jun B and Jun D have been shown ... C-terminal regions, which are involved in dimerization and ... involved in transcriptional activation, diverge. ...
IHC Zinc Fixative - , 1000 ml Consult technical datasheet for details....
Biology Products: